Does consolidation durvalumab increase the risk of pneumonitis in Stage III NSCLC?  

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice